Across TCGA pan-cancer cohorts, ATF6B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ATF6B data layer compared with 26 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATF6B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATF6B expression acts as an unfavorable survival marker.
GBM are the cancer types where ATF6B mass-spec protein most reproducibly stratifies survival.